Ertapenem
Dosing in kidney impairment
Patients with Renal Impairment Ertapenem for injection may be used for the treatment of infections in adult patients with renal impairment. In patients whose creatinine clearance is >30 mL/min/1.73 m 2 , no dosage adjustment is necessary. Adult patients with severe renal impairment (creatinine clearance ≤30 mL/min/1.73 m 2 ) and end-stage renal disease (creatinine clearance ≤10 mL/min/1.73 m 2 ) should receive 500 mg daily.
A supplementary dose of 150 mg is recommended if ertapenem is administered within 6 hours prior to hemodialysis. There are no data in pediatric patients with renal impairment.
Patients on Hemodialysis When adult patients on hemodialysis are given the recommended daily dose of 500 mg of ertapenem for injection within 6 hours prior to hemodialysis, a supplementary dose of 150 mg is recommended following the hemodialysis session. If ertapenem for injection is given at least 6 hours prior to hemodialysis, no supplementary dose is needed.
There are no data in patients undergoing peritoneal dialysis or hemofiltration. There are no data in pediatric patients on hemodialysis. When only the serum creatinine is available, the following formula Cockcroft and Gault equation: Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976 may be used to estimate creatinine clearance.
The serum creatinine should represent a steady state of renal function. [See table below.]
| Infectiondue to the designated pathogens [see Indications and Usage (1)] | Daily Dose (IV or IM) Adults and Pediatric Patients 13 years of age and older | Daily Dose (IV or IM) Pediatric Patients 3 months to 12 years of age | Recommended Duration of Total Antimicrobial Treatment |
|---|---|---|---|
| Complicated intra-abdominal infections | 1 g | 15 mg/kg twice dailynot to exceed 1 g/day | 5 to 14 days |
| Complicated skin and skin structure infections, including diabetic foot infectionsErtapenem for injection has not been studied in diabetic foot infections with concomitant osteomyelitis [see Clinical Studies (14.1)]. | 1 g | 15 mg/kg twice daily | 7 to 14 daysadult patients with diabetic foot infections received up to 28 days of treatment (parenteral or parenteral plus oral switch therapy) |
| Community acquired pneumonia | 1 g | 15 mg/kg twice daily | 10 to 14 daysduration includes a possible switch to an appropriate oral therapy, after at least 3 days of parenteral therapy, once clinical improvement has been demonstrated. |
| Complicated urinary tract infections, including pyelonephritis | 1 g | 15 mg/kg twice daily | 10 to 14 days |
| Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections | 1 g | 15 mg/kg twice daily | 3 to 10 days |
Dosing in liver impairment
Patients with Hepatic Impairment No dose adjustment recommendations can be made in patients with hepatic impairment [see Use in Specific Populations and Clinical Pharmacology ].
Preparation and administration
Preparation and Reconstitution for Administration Vials Adults and pediatric patients 13 years of age and older Preparation for intravenous administration : DO NOT MIX OR CO-INFUSE ERTAPENEM FOR INJECTION WITH OTHER MEDICATIONS. DO NOT USE DILUENTS CONTAINING DEXTROSE (α-D-GLUCOSE). ERTAPENEM FOR INJECTION MUST BE RECONSTITUTED AND THEN DILUTED PRIOR TO ADMINISTRATION.
Reconstitute the contents of a 1 g vial of ertapenem for injection with 10 mL of one of the following: Water for Injection, 0.9% Sodium Chloride Injection or Bacteriostatic Water for Injection, using a syringe equipped with a 21-gauge or smaller diameter needle. NOTE: Use with a needleless IV system is not recommended. Shake well to dissolve and immediately transfer contents of the reconstituted vial to 50 mL of 0.9% Sodium Chloride Injection.
Complete the infusion within 6 hours of reconstitution. Preparation for intramuscular administration: ERTAPENEM FOR INJECTION MUST BE RECONSTITUTED PRIOR TO ADMINISTRATION. Reconstitute the contents of a 1 g vial of ertapenem for injection with 3.2 mL of 1.0% lidocaine HCl injection Refer to the prescribing information for lidocaine HCl. ( without epinephrine ).
Shake vial thoroughly to form solution. Immediately withdraw the contents of the vial and administer by deep intramuscular injection into a large muscle mass (such as the gluteal muscles or lateral part of the thigh). The reconstituted IM solution should be used within 1 hour after preparation. NOTE: THE RECONSTITUTED SOLUTION SHOULD NOT BE ADMINISTERED INTRAVENOUSLY .
Pediatric patients 3 months to 12 years of age Preparation for intravenous administration: DO NOT MIX OR CO-INFUSE ERTAPENEM FOR INJECTION WITH OTHER MEDICATIONS. DO NOT USE DILUENTS CONTAINING DEXTROSE (α-D-GLUCOSE). ERTAPENEM FOR INJECTION MUST BE RECONSTITUTED AND THEN DILUTED PRIOR TO ADMINISTRATION. Reconstitute the contents of a 1 g vial of ertapenem for injection with 10 mL of one of the following: Water for Injection, 0.9% Sodium Chloride Injection or Bacteriostatic Water for Injection, using a syringe equipped with a 21-gauge or smaller diameter needle.
NOTE: Use with a needleless IV system is not recommended. Shake well to dissolve and immediately withdraw a volume equal to 15 mg/kg of body weight (not to exceed 1 g/day) and dilute in 0.9% Sodium Chloride Injection to a final concentration of 20 mg/mL or less. Discard vial with unused portion of ertapenem for injection reconstituted solution.
Complete the infusion within 6 hours of reconstitution. Preparation for intramuscular administration: ERTAPENEM FOR INJECTION MUST BE RECONSTITUTED PRIOR TO ADMINISTRATION. Reconstitute the contents of a 1 g vial of ertapenem for injection with 3.2 mL of 1.0% lidocaine HCl injection ( without epinephrine ). Shake vial thoroughly to form solution.
Immediately withdraw a volume equal to 15 mg/kg of body weight (not to exceed 1 g/day) and administer by deep intramuscular injection into a large muscle mass (such as the gluteal muscles or lateral part of the thigh). Discard vial with unused portion of ertapenem for injection reconstituted solution. The reconstituted IM solution should be used within 1 hour after preparation.
NOTE: THE RECONSTITUTED SOLUTION SHOULD NOT BE ADMINISTERED INTRAVENOUSLY . Storage When prepared with the diluent, ertapenem for injection maintains satisfactory potency for 6 hours at room temperature (25°C) or for 24 hours under refrigeration (5°C) and used within 4 hours after removal from refrigeration. Solutions of ertapenem for injection should not be frozen .
Before administering, see accompanying package circular for ertapenem for injection. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to use, whenever solution and container permit. Solutions of ertapenem for injection range from colorless to pale yellow. Variations of color within this range do not affect the potency of the product.